Since its establishment in 2017, SpringWorks Therapeutics has been focused on developing and delivering life-changing medicines for individuals with severe rare diseases and cancer. The company applies a precision medicine approach to its work, building a diversified targeted oncology pipeline that includes clinical trials for rare tumor types and genetically defined cancers. In 2021, their first FDA-approved therapy, OGSIVEO®, was launched to treat adult patients with progressing desmoid tumors requiring systemic treatment.
SpringWorks Therapeutics’ strategic approach and operational expertise in clinical development have allowed them to advance lead product candidates into late-stage trials and establish collaborations with various industry and academic partners to maximize the potential of their portfolio. The company is dedicated to providing more solutions for cancer patients by continuing to develop new therapies that will make a significant impact on their lives.
On May 14th, 2024, management at SpringWorks Therapeutics will be participating in a fireside chat at the BofA Securities 2024 Health Care Conference in Las Vegas, Nevada. The chat is scheduled for 3:40 p.m. PT / 6:40 p.m. ET and will be accessible via a live webcast on the Events & Presentations page on the company’s website at https://ir.springworkstx.com/. A replay of the webcast will be available on the website for a limited time after the conference.
For more information about SpringWorks Therapeutics, visit www.springworkstx.com and follow @SpringWorksTx on social media platforms like X (formerly Twitter), LinkedIn, and YouTube. For any inquiries, you can contact Kim Diamond, Vice President of Communications and Investor Relations at 203-561-1646 or kdiamond@springworkstx.com or Samantha Hilson Sandler, Senior Director of Investor Relations at 203-461-5501 or samantha
